"For over 45 years, Piedmont Eye Center has been a trusted name in eye care in the Central Virginia area. With 9 eye care specialists, Piedmont Eye Center is Lynchburg’s largest ophthalmology center. Our doctors use only the latest and best technology to diagnose and treat various eye diseases. Our doctors are local, living in your community, to offer convenient care that fits your busy lifestyle. You'll find yourself at home in the hands of caring doctors who all have the same goal; to give your eyes the best care possible. We understand how unique your eyes are and offer personalized care. Whether treating or diagnosing, our surgeons are here to take care of you."

During the past decade, Piedmont Eye Center conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 9 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 8 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Piedmont Eye Center" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Allergan" with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Shire" with 2 trials sponsored and "Aerie Pharmaceuticals" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Piedmont Eye Center" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator, "IQVIA Biotech" with 1 trials as a collaborator and "ORA, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Piedmont Eye Center" are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (2 trials), "Dry Eye Syndromes" (2 trials), "Macular Degeneration" (2 trials) and "Neovascular Age-related Macular Degeneration" (2 trials). Many other conditions were trialed in "Piedmont Eye Center" in a lesser frequency.

Most popular intervention types in "Piedmont Eye Center" are "Drug" (23 trials), "Other" (7 trials), "Procedure" (3 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (7 trials), "Faricimab" (6 trials), "Aflibercept" (4 trials), "Placebo" (4 trials) and "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials). Other intervention names were less common.

The vast majority of trials in "Piedmont Eye Center" are 24 trials for "All" genders.

Currently, there are NaN active trials in "Piedmont Eye Center". undefined are not yet recruiting, 4 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Piedmont Eye Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Piedmont Eye Center, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".